Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease | Center for Neurodegeneration and Translational Neuroscience (CNTN)

Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C

Alzheimer’s Res Ther

January 2019

← Back to Publications